Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

122 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-27

Study Completion Date

2022-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and rapidly approved. Novel mRNA vaccines such as the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have reported a stunning \>94% efficacy against COVID-19. However, global access has not been equitable, with many low- and middle-income countries having no vaccine access or access under emergency use mainly to traditional inactivated SARS-CoV2-2 vaccines such as BBIBP-CorV (Sinopharm Beijing), CoronaVac (Sinovac) and BBV152 (Bharat Biotech). Emerging studies have shown that lower concentrations of neutralizing antibodies (Nab) are attained after CoronaVac than after a mRNA-based vaccine in healthy individuals. This difference seems to be more pronounced in immunocompromised patients who are at higher risk of severe COVID-19 and death from COVID-19. As such several countries including United States, Israel and Chile have recommended a third vaccine dose for this vulnerable population.

In this observational study we will explore the humoral response to the BNT162b2 vaccine in patients who received two previous doses of the inactivated vaccine Coronavac or two doses of BNT162b2.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients

NCT05313074

COVID-19 Cancer

COMPLETED NA

Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients

NCT04910295

Cancer Covid19

COMPLETED

Vaccination Against COVID-19 in Cancer

NCT04715438

Cancer

ACTIVE_NOT_RECRUITING NA

Immune Response to the COVID-19 Vaccine

NCT04936997

Covid19 Cancer Malignancy +1 more

COMPLETED EARLY_PHASE1

Responses to COVID-19 Vaccination in Patients With Cancer

NCT04745377

Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sars-CoV-2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Three doses of BNT162b2.

Cancer patients on active cytotoxic treatment who received three doses of BNT162b2.

Three doses of BNT162b2 (observational)

Intervention Type BIOLOGICAL

BNT162b2 (COVID 19 mRNA vaccine)

Two doses of Coronavac and one of BNT162b2.

Cancer patients on active cytotoxic treatment who received two doses of Coronavac and one dose of BNT162b2.

Two doses of Coronavac and one dose BNT162b2 (observational)

Intervention Type BIOLOGICAL

BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Three doses of BNT162b2 (observational)

BNT162b2 (COVID 19 mRNA vaccine)

Intervention Type BIOLOGICAL

Two doses of Coronavac and one dose BNT162b2 (observational)

BNT162b2 (COVID 19 mRNA vaccine) Coronavac (COVID 19 inactive vaccine)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Vaccination with two doses of Coronavac vaccine or BNT162b2 vaccine
* Eastern Cooperative Oncology group performance status \< 3

Exclusion Criteria

* Previous SARS-CoV-2 infection
* Vaccination with booster vaccine more than 12 weeks before informed consent
* Intravenous inmunoglobulin therapy 60 days before informed consent
* Any condition that could interfere with the paticipant´s participation during the study in the opinion of the treating investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No